Showing 3261-3270 of 4131 results for "".
- New Analysis Provides Evidence-based Recommendations for Vitiligo in Pediatric Patientshttps://practicaldermatology.com/news/evidence-based-recommendations-for-treating-vitiligo-in-pediatric-patients-insights-from-comprehensive-review/2462436/A new consensus statement published in JAMA Dermatology provided evidence-based expert recommendations for the treatment of vitiligo in pediatric, adolescent, and young adult patients. The authors undertook a rigorous examination of existing literature and expert consensus, aimi
- Povorcitinib Shows Efficacy and Safety in Patients with Prurigo Nodularishttps://practicaldermatology.com/news/study-povorcitinib-safe-and-effective-for-prurigo-nodularis/2462426/The oral JAK1 inhibitor povorcitinib was shown to improve itch in prurigo nodularis, and also met its primary endpoints, according to new phase 2 data presented at the American Academy of Dermatology 2024 Annual Meeting in San Diego. Researchers for the study enrolled 146 participants and
- PSORRO: Oral Roflumilast Linked with Weight Loss in Patients with Psoriasishttps://practicaldermatology.com/news/effects-of-oral-roflumilast-therapy-on-body-weight-and-cardiometabolic-parameters-in-patients-with-psoriasis-results-from-a-randomized-controlled-trial-psorro/2462256/Roflumilast was associated with a decrease in appetite and weight loss in patients with psoriasis, according to a new study in JAAD. "Recent evidence indicates that roflumilast holds a therapeutic potential in psoriasis, a chronic inflammatory disease linked to overweight/
- 595-nm Pulsed Dye Laser with 1565-nm Nonablative Fractional Laser Safe, Effective for Acnehttps://practicaldermatology.com/news/treatment-of-erythematous-acne-scars-using-595-nm-pulsed-dye-laser-combined-with-1565-nm-resurfx-nonablative-fractional-laser/2462257/The use of a 595-nm pulsed dye laser (PDL) and 1565-nm nonablative fractional laser (NAFL) was seen as safe and efficacious in patients with acne vulgarism, according to a new study in the Journal of Cosmetic Dermatology. "Acne erythema has been considered simple ery
- CD19 CAR T-Cell Transfer Therapy Shows Promise for Systemic Lupus Erythematosushttps://practicaldermatology.com/news/cd19-car-t-cell-transfer-therapy-and-systemic-lupus-erythematosus/2462248/Results from a recent analysis in the New England Journal of Medicine suggested a potentially effective approach for treating autoimmune diseases like systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis. The case series analysi
- Study Highlights Fatigue Experienced by Psoriasis Patientshttps://practicaldermatology.com/news/study-highlights-fatigue-experienced-in-psoriasis/2462247/A new analysis in the Journal of the American Academy of Dermatology sought to tease out drivers of fatigue in patients with psoriasis (PsO) and psoriatic arthritis (PsA). Researchers for the study examined various factors contributing to fatigue in these individuals using
- Large Registries Leave Data Gaps for Melanoma in Black Patientshttps://practicaldermatology.com/news/large-registries-leave-gaps-in-data-on-melanoma-in-black-patients/2462232/New research published in JAMA Dermatology provides crucial patient-level and tumor-level insights into melanoma in Black patients that has been lacking in large registiries.
- Study Reveals TikTok's Impact on Psoriasis Treatment Understandinghttps://practicaldermatology.com/news/study-reveals-tiktoks-impact-on-psoriasis-treatment-understanding/2462223/A new study published in the Journal of Drugs in Dermatology offers a glimp
- Guselkumab Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Colorhttps://practicaldermatology.com/news/tremfya-guselkumab-demonstrates-significant-and-rapid-scalp-psoriasis-clearance-in-people-of-color-in-new-large-phase-3b-study/2462218/At the Maui Derm Hawaii 2024 conference, Johnson & Johnson presented topline data from Cohort B in the Phase 3b VISIBLE study that demonstrated that TREMFYA® (guselkumab) showed rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement
- Upadacitinib in Atopic Dermatitis: New Safety Data Encourages Practitioners and Patientshttps://practicaldermatology.com/news/long-term-safety-of-upadacitinib-in-atopic-dermatitis-5-year-analysis-unveils-encouraging-results/2462210/A recent analysis reveals that upadacitinib, an oral Janus kinase 1 (JAK1) inhibitor, maintains its safety profile over a span of 5 years, aiding individuals